Trials / Completed
CompletedNCT01390792
Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 622 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza virus infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanamivir hydrate |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2009-02-01
- Completion
- 2009-05-01
- First posted
- 2011-07-11
- Last updated
- 2017-05-16
Source: ClinicalTrials.gov record NCT01390792. Inclusion in this directory is not an endorsement.